INTERNATIONAL FLAVORS & FRAGRANCES INC
IFFAPI behind this page
IFF Q2 2025 request
Playground key active
/api/financials?ticker=IFF&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 2,764 | 2,889 | -4.3% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 850 | 847 | +0.4% |
| Health Biosciences · Operating Segments | 577 | 556 | +3.8% |
| Pharma Solutions · Operating Segments | 103 | 273 | -62.3% |
| Scent · Operating Segments | 603 | 603 | 0.0% |
| Taste · Operating Segments | 631 | 610 | +3.4% |
Show Geography breakouts |
|||
| All Foreign Countries · Geographic Concentration Risk | 2,000 | 2,067 | -3.2% |
| Asia | 647 | 681 | -5.0% |
| EMEA | 953 | 972 | -2.0% |
| Latin America | 361 | 360 | +0.3% |
| North America | 803 | 876 | -8.3% |
| US · Geographic Concentration Risk | 764 | 822 | -7.1% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,764 | 2,889 | -4.3% |
| Cost of Revenue | 1,734 | 1,821 | -4.8% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 642 | 655 | -2.0% |
| Health Biosciences · Operating Segments | 311 | 294 | +5.8% |
| Pharma Solutions · Operating Segments | 68 | 187 | -63.6% |
| Scent · Operating Segments | 336 | 328 | +2.4% |
| Taste · Operating Segments | 377 | 357 | +5.6% |
| Gross Profit | 1,030 | 1,068 | -3.6% |
| Research & Development | 182 | 173 | +5.2% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 14 | 21 | -33.3% |
| Health Biosciences · Operating Segments | 55 | 50 | +10.0% |
| Pharma Solutions · Operating Segments | 3 | 7 | -57.1% |
| Scent · Operating Segments | 62 | 55 | +12.7% |
| Taste · Operating Segments | 47 | 40 | +17.5% |
| Selling, General & Administrative | 483 | 493 | -2.0% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 104 | 94 | +10.6% |
| Health Biosciences · Operating Segments | 91 | 89 | +2.2% |
| Pharma Solutions · Operating Segments | 10 | 26 | -61.5% |
| Scent · Operating Segments | 92 | 93 | -1.1% |
| Taste · Operating Segments | 98 | 100 | -2.0% |
| Operating Income | 198 | 191 | +3.7% |
| Interest Income | 7 | 3 | +133.3% |
| Other Non-Operating Income (Expense) | 10 | 15 | -33.3% |
| Income Before Taxes | 534 | 183 | +191.8% |
| Income Tax Expense (Benefit) | -78 | 11 | -809.1% |
| Net Income | 612 | 172 | +255.8% |
| Net Income | 612 | 170 | +260.0% |
| Comprehensive Income | 1,320 | 46 | +2769.6% |
| EPS (Basic) | 2.39 | 0.67 | +256.7% |
| EPS (Diluted) | 2.38 | 0.66 | +260.6% |
| Wtd Avg Shares (Basic) | 256 | 255 | +0.4% |
| Wtd Avg Shares (Diluted) | 257 | 256 | +0.4% |
| Interest Expense | 61 | 79 | -22.8% |
| Foreign Currency Transaction Gain Loss Before Tax | -17 | -33 | +48.5% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 816 | 671 | +21.6% |
| Inventory | 2,371 | 2,160 | +9.8% |
| Total Current Assets | 5,928 | 8,149 | -27.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,905 | 3,763 | +3.8% |
| Operating Lease Right-of-Use Assets | 620 | — | — |
| Goodwill | 8,283 | 9,282 | -10.8% |
Show Business Segments breakouts |
|||
| Health Biosciences | 4,467 | 4,342 | +2.9% |
| Scent | 1,511 | 1,478 | +2.2% |
| Taste | 2,305 | — | — |
| Intangible Assets | 6,430 | — | — |
| Other Non-Current Assets | 955 | — | — |
| Total Assets | 26,121 | 29,543 | -11.6% |
| Current Liabilities | |||
| Accounts Payable | 1,348 | 1,272 | +6.0% |
| Current Portion of Long-Term Debt | -500 | -783 | +36.1% |
| Total Current Liabilities | 3,183 | 3,425 | -7.1% |
| Debt Current | 500 | 783 | -36.1% |
| Non-Current Liabilities | |||
| Long-Term Debt | 5,684 | 8,596 | -33.9% |
| Deferred Tax Liabilities | 1,387 | 1,833 | -24.3% |
| Other Non-Current Liabilities | 680 | — | — |
| Stockholders' Equity | |||
| Common Stock | 35 | 35 | 0.0% |
| Retained Earnings | -3,215 | -2,414 | -33.2% |
| Accumulated Other Comprehensive Income | -1,415 | — | — |
| Total Stockholders' Equity | 14,404 | 14,254 | +1.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -148 | -237 | +37.6% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -3 | -5 | +40.0% |
| Accumulated Other Comprehensive Income | -1,415 | -2,315 | +38.9% |
| Accumulated Translation Adjustment | -1,264 | -2,073 | +39.0% |
| Total Liabilities & Equity | 26,121 | 29,543 | -11.6% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 478 | 524 | -8.8% |
| Stock-Based Compensation | 51 | 43 | +18.6% |
| Deferred Income Taxes | -163 | -77 | -111.7% |
| Change in Accounts Receivable | -106 | -293 | +63.8% |
| Change in Inventory | -124 | 4 | -3200.0% |
| Change in Accounts Payable | 77 | 54 | +42.6% |
| Net Cash from Operations | 368 | 336 | +9.5% |
| Investing Activities | |||
| Capital Expenditures | -274 | -200 | -37.0% |
| Net Cash from Investing | 2,541 | 664 | +282.7% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -22 | -14 | -57.1% |
| Debt Repayments (YTD) | — | — | — |
Show Debt Instrument breakouts |
|||
| A2026 Term Loan · Loans Payable | 413 | 31 | +1232.3% |
| Net Cash from Financing | -2,654 | -1,023 | -159.4% |
| Supplemental | |||
| Interest Paid | 130 | 158 | -17.7% |
| Unpaid Capital Expenditures | 69 | 64 | +7.8% |
| Other Cash Flow | |||
| Net Change in Cash | 345 | -61 | +665.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.